Biogen Inc. has announced the initiation of a Phase 3 study, named PROMINENT, to assess the efficacy and safety of felzartamab in the treatment of primary membranous nephropathy $(PMN)$. This global study will compare felzartamab, an investigational anti-CD38 monoclonal antibody, with tacrolimus in adults with PMN, a rare immune-mediated kidney disease currently lacking approved therapies. The study aims to address the unmet medical need for this condition, which affects approximately 36,000 patients in the U.S. alone. This marks the third Phase 3 trial of felzartamab initiated by Biogen this year, following studies for late antibody-mediated rejection in adult kidney transplant recipients and IgA nephropathy. The results of the PROMINENT study have not yet been presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.